← Back to front page
United States · Platforms & data · MarketBeat

Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows

Published by MarketBeat · United States 19 min ago
Image from MarketBeat Media, LLC.
Image from MarketBeat Media, LLC. · MarketBeat

Detailed summary

Evolus (NASDAQ:EOLS) executives said the company expects its expanding lineup of injectable aesthetics products to support growth as it prepares for the anticipated launch of Evolysse Sculpt in 2027. At a company event, CEO and President David Moatazedi said Evolus has diversified beyond its flagsh

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading